ClinicalTrials.gg
CompletedNCT01595425Updated Dec 12, 2012

Bioequivalence Study Comparing D961H Sachet and D961H Capsule in Japanese Healthy Male Subjects

A Phase 1 interventional study of D961H Sachet 20 mg and D961H HPMC capsule 20 mg in Bioequivalence Study, sponsored by AstraZeneca. Completed at 1 site in Japan. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-12-12.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

This study is to investigate whether D961H sachet 20 mg is bioequivalent to D961H HPMC capsule 20 mg following repeated oral doses, and to evaluate the safety and tolerability of these two formulations in healthy male Japanese subjects.

Read the detailed description

A Phase I, Open-label, Randomized, Single-center, 2-way Crossover Bioequivalence Study Comparing a Pellets Based Sachet Formulation of D961H 20 mg and a Commercial HPMC Capsule of D961H 20 mg After Repeated Oral Administration in Japanese Healthy Male Subjects

02

Conditions studied

  • Bioequivalence Study

Keywords

  • Bioequivalence,
  • pharmacokinetics,
  • safety,
  • esomeprazole,
  • Japanese,
  • healthy subject,
  • homo-EM
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written prior to any study specific procedures
  2. Japanese healthy male subjects aged 20 to 45 years of age
  3. 19-27 kg/m2 and body weight 50-85 kg
  4. Clinically normal findings
  5. Classified as homo-EM(extensive metabolizers) according to the genotype of CYP2C19

Exclusion criteria

Exclusion Criteria:

  1. Significant clinical illness
  2. Past or present cardiac, renal, hepatic, neurological or gastrointestinal disease
  3. Clinical significant condition which could modify the absorption of the product
  4. Past or present severe allergic disease, to food or drugs, or allergic symptoms requiring medical intervention
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    D961H Sachet 20 mg

    2 way crossover

    Drug: D961H Sachet 20 mg

  • Experimental
    D961HHPMC Capsule 20 mg

    2 way crossover

    Drug: D961H HPMC capsule 20 mg

Interventions

  • Each volunteer will receive a D961H sachet 20 mg once in the morning for 5 days.

    Also known as: esomeprazole sachet

  • Each volunteer will receive a D961H HPMC capsule 20 mg once in the morning for 5 days.

    Also known as: esomeprazole, capsule 20 mg

06

What researchers measure

Primary outcomes

  1. AUCτ and Cmax,ss of D961H

    * AUC(0-t)-Area under plasma concentration time curve from zero to time of the last measurable concentration * Cmax,ss - maximum concentration at steady state

    Time frame: Day 5

Secondary outcomes

  1. Profile of pharmacokinetic of D961H in terms of AUC0-t,ss, MRT, tmax,ss, and t1/2.

    * AUC0-t,ss-Area under plasma concentration time curve from zero to time of the last measurable concentration at steady state * MRT- Mean residence time * tmax,ss -time of maximum concentration at steady state * t½ -Terminal half-life

    Time frame: Day 5

  2. Safety and tolerability of a D961H in terms of clinical laboratory tests, blood pressure, pulse rate and body temperature.

    Time frame: Up to 5 to 7 days after the last dose.

  3. Number of participants with adverse events.

    Time frame: Up to 5 to 7 days after the last dose.

07

Study locations

1 site
  • Research Unit
    Fukuoka-shi, Fukuoka, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2012
First posted
May 10, 2012
Start
May 2012
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Last update
Dec 12, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01595425
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 10, 2012
Start date
May 2012
Primary completion
Jun 2012
Completion
Jun 2012
Last update
Dec 12, 2012

Study contacts

Masataka Date
study director · AstraZeneca R&D Japan
Masanari Shiramoto
principal investigator · Hakata Clinic
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: D961H

Start the discussion